NCT05273528

The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine

A Single Arm, Open Label Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of V-01-351/V-01D Bivalence Vaccine in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: Livzon Pharmaceutical Group Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

It is a Single Arm, Open Label Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of V-01-351/V-01D Bivalence Vaccine in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines. A total of 20 participants were enrolled.

Conditions

• COVID-19 Pandemic

Interventions

Type	Name	Description
BIOLOGICAL	Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine	The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Timeline

• Start date: 2022-01-11
• Primary completion: 2023-01-06
• Completion: 2023-01-06
• First posted: 2022-03-10
• Last updated: 2022-03-10

Locations

1 site across 1 country: China